Late-stage, primary open-angle glaucoma in Europe: Social and health care maintenance costs and quality of life of patients from 4 countries

Current Medical Research and Opinion

Volumn 24, Issue 6, 2008, Pages 1763-1770

  Thygesen, J ^a   Aagren, M ^b   Arnavielle, S ^c   Bron, A ^c   Frohlich S J ^d   Baggesen, K ^e   Azuara Blanco, A ^f   Buchholz, Patricia ^g   Walt, J G ^h  

^a Rigshospitalet   (Denmark)

^b Muusmann Research and Consulting   (Denmark)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF MUNICH   (Germany)

^e Low Vision Centre   (Denmark)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

^g ALLERGAN PLC   (United States)

^h ALLERGAN INC   (United States)

Author keywords

Costs; Glaucoma; Quality of life; Visual acuity

Indexed keywords

ADULT; AGED; CONFERENCE PAPER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DENMARK; DISEASE SEVERITY; FEMALE; FRANCE; GERMANY; HEALTH CARE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; QUALITY OF LIFE; REHABILITATION CENTER; SCORING SYSTEM; SOCIAL CARE; TELEPHONE; UNITED KINGDOM; VISUAL ACUITY; VISUAL IMPAIRMENT;

AGED; AGED, 80 AND OVER; COST OF ILLNESS; EUROPE; FEMALE; GLAUCOMA; HEALTH EXPENDITURES; HEALTH SERVICES; HEALTH STATUS; HUMANS; INTERVIEWS AS TOPIC; MALE; MEDICAL AUDIT; MIDDLE AGED; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SELF-HELP DEVICES;

EID: 46449127701     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802111068     Document Type: Conference Paper

References (29)

1. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:1711-20
2. Sommer A. Glaucoma risk factors observed in the Baltimore Eye Survey. Curr Opin Ophthalmol 1996;7:93-8
3. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7
4. Lafuma A, Brezin A, Lopatriello S, et al. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the United Kingdom. Pharmacoeconomics 2006;24:193-205
5. Buch H, Vinding T, La Cour M, et al. The prevalence and causes of bilateral and unilateral blindness in an elderly urban Danish population. The Copenhagen City Eye Study. Acta Ophthalmol Scand 2001;79:441-9
6. Klaver CC, Wolfs RC, Vingerling JR, et al. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998;116:653-8
7. Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol 2005;89:1245-9
8. Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 2006;124:12-9
9. Gieser DK, Tracy WR, O'Connell W, et al. Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a US multisite retrospective study. J Glaucoma 2006;15:419-25
10. Poulsen PB, Buchholz P, Walt JG, et al. Cost analysis of glaucoma-related blindness in Europe. International Congress Series 2005;1282:262-6
11. Gupta V, Srinivasan G, Mei SS, et al. Utility values among glaucoma patients: an impact on the quality of life. Br J Ophthalmol 2005;89:1241-4
12. Kobelt G, Jonsson B, Bergstrom A, et al. Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand 2006;84:363-71
13. CRPM centre de Reeducation pour Malvoyants. Official prices from Assurance Maladie. 2006
14. Curtis L, Netten A. Unit Costs of Health and Social Care. Canterbury: PSSRU at University of Kent; 2004
15. Fees for service in primary sector. Danish Medical Association. 2005. Available at: www.laeger.dk. [Last accessed December 2006]
16. Takstsystem 2006 - en vejledning. March 2006. Available at: http://www.sst.dk/publ/Publ2006/SESE/Takstsystem/Takstsystem2006.pdf [Last accessed 05 Feb 2008]
17. NHS reference costs. Department of Health. 2004. Available at: http://www.dh.gov.uk/PublicationsAndStatistics/Publications/ PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en? CONTENT_ID=4105545&chk=znAfqu. [Last accessed May 2006]
18. Krauth C, Hessel F, Hansmeier T, et al. Empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation. Gesundheitswesen 2005;67:736-46
19. L'Assurance Maladie. Available at: http://www.codage.ext.cnamts.fr. [Last accessed October 2005]
20. Le Pen C, Ligier M, Berdeaux G. Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom. J Med Econ 2005;8:67-84
21. Service-public. Available at: www.service-public.fr. [Last accessed October 2005]
22. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72
23. Coons SJ, Rao S, Keininger DL, et al. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 2000;17:13-35
24. Drummond MF, O'Brien BJ, Stoddard GL, et al. Methods for the Economic Evaluation of Health Care Programmes, 2nd ed. Oxford: Oxford University Press; 2007
25. Dolan P, Gudex C, Kind P, et al. A social tariff for Euroqol: results from a United Kingdom general population survey. Centre for Health Economics, Discussion Paper 138. University of York; 1995
26. Raina P, Wong M, Massfeller H. The relationship between sensory impairment and functional independence among elderly. BMC Geriatr 2004;4:3
27. Statistics Denmark 2006 Available at: http://www.dst.dk/. [Last accessed January 2006]
28. Montemayor F, Sibley LM, Courtright P, et al. Contribution of multiple glaucoma medications to visual function and quality of life in patients with glaucoma. Can J Ophthalmol 2001;36:385-90
29. Aspinall PA, Brice R, Vickers A, et al. Methodological issues arising from three studies which included conjoint analysis in visually impaired people. Poster presented at: ISPOR 10th Annual European Congress, 20-23 October 2007; Dublin, Ireland